We reach more than 65,000 registered users in Dec!! Register Now
Needing more viruses, Novartis taps Catalent to boost manufacturing of its new gene therapy Zolgensma
- July 21, 2019
- 105 Views
- 0 Likes
- 0 Comment
Virus shortages are forcing gene therapy firms to build their own manufacturing facilities and work with contract manufacturers at the same time
Cite This Article as
"Needing more viruses, Novartis taps Catalent to boost manufacturing of its new gene therapy Zolgensma", MachPrinciple, July 21, 2019, https://machprinciple.com/post/Needing-more-viruses-Novartis-taps-Catalent-to-boost-manufacturing-of-its-new-gene-therapy-Zolgensma
No tags found for this post
